The Clusterbusters Survey | Preliminary Data from ~2000 Respondents - REMAP Therapeutics

Return to course: The Psychedelics & Pain Symposium 2024

Previous Lesson Previous Next Next Lesson

The Psychedelics & Pain Symposium 2024

Welcome, Introduction to Psychedelics for Pain & Physical Conditions
Best Practices, Harm Reduction, & Pharmaceutical Interactions
The Complexity of Chronic Pain & Why Psychedelics Might Help
Clinical Trials of Psychedelics in Headache Disorders
New Directions in Psychedelic Therapy: Exploring Psilocybin for Post-Treatment Lyme Disease
Patient Perspective: Treating long-COVID with MDMA & Psilocybin
Neural Signatures of Pain Patients on Psilocybin
Promise/Peril of Citizen-science in Psychedelic Research for Pain
Psychedelic Access & Policy
Grow, Source, & Test Your Medicines
Patient Perspective: Sacred Plants & Ceremonial Doctoring for Chronic Pain

Welcome, Introduction, Review of Day One
LSD-assisted Psychotherapy to Treat Metastatic Cancer-induced Bone Pain
Analgesic Effects of Psychedelics: From Surveys to the Lab
Analgesic Potential of Low-Dose Psychedelics & Cathinones for Pain
Proposed Mechanisms of Psychedelics for Pain & Implications for Patient-Centered Care
The Clusterbusters Survey | Preliminary Data from ~2000 Respondents
Patient Perspective | Psilocybin for CPRS & Complex Chronic Pain
Psychedelics are Powerful Anti-inflammatory Agents
Fear & Flexibility: How Psilocybin Reshapes Cortical Serotonergic Brain Circuits After Trauma

The Clusterbusters Survey | Preliminary Data from ~2000 Respondents

Please log in to view your account.

Username

Password

Remember Me

Forgot Password